Articles, guides, and regulatory updates from our community.
A 2026 study found BPC-157 and hybrid analogs may inhibit acetylcholinesterase, a key enzyme in Alzheimer's disease. Learn what the research means.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's development barriers, formulation challenges, and why human clinical data remains critically limited.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team
New research explores how mitochondria-targeted peptide nanoparticles may protect the liver from ischemia-reperfusion injury. Learn what the science shows.
By Peptide Association Research Team